CSPI on kava
This article was originally published in The Tan Sheet
Executive Summary
FDA's request for healthcare practitioner data linking botanical with hepatotoxicity "in and of itself is not sufficient to protect consumers," Center for Science in the Public Interest says in Jan. 28 letter. Agency should request manufacturers, retailers to temporarily halt sales pending FDA determination of safety issues. "FDA should also issue an advisory to consumers explaining the concerns that have been raised and advise them to consult with their physicians before taking any products that contain kava," group maintains...